Study of no Pharmacokinetic Interaction Between Rosuvastatin 20mg and Ezetimibe10mg, Fixed Dose vs Individual Components
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2021-08-24
- Lead Sponsor
- Laboratorios Silanes S.A. de C.V.
- Target Recruit Count
- 36
- Registration Number
- NCT04895059
- Locations
- 🇲🇽
Laboratorio Silanes, S.A. de C.V., Mexico City, Mexico
Efficacy and Safety of the Fixed-dose Combination Atorvastatin/Fenofibrate vs Atorvastatin in Patients With T2D and DLP.
Phase 3
- Conditions
- Dyslipidemia Associated With Type II Diabetes Mellitus
- Interventions
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Laboratorios Silanes S.A. de C.V.
- Target Recruit Count
- 78
- Registration Number
- NCT04882293
- Locations
- 🇲🇽
Laboratorio Silanes, S.A. de C.V., Mexico City, Mexico
Study to Evaluate the Safety of the Fixed-dose Combination Rosuvastatin/Ezetimibe for Patients With Dyslipidaemia
Completed
- Conditions
- Dyslipidemias
- Interventions
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Laboratorios Silanes S.A. de C.V.
- Target Recruit Count
- 120
- Registration Number
- NCT04862962
- Locations
- 🇲🇽
Laboratorio Silanes, S.A. de C.V., Mexico City, Mexico
Pharmacokinetic Study Protocol of ANAWIDOW Lyophilized Powder for Solution for Intravenous Use in Fasting Conditions
Phase 1
Completed
- Conditions
- Latrodectism
- Interventions
- Drug: ANAWIDOW [antivenin latrodectus (black widow) equine immune F(ab)2] lyophilized powder for solution 10 mL
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Laboratorios Silanes S.A. de C.V.
- Target Recruit Count
- 16
- Registration Number
- NCT04848714
- Locations
- 🇲🇽
Laboratorio Silanes, S.A. de C.V., Ciudad de mexico, Mexico City, Mexico
Oral Combination of Glimepiride/Vildagliptin/Metformin in Patients With T2D and Dual Treatment Failure
Phase 3
Recruiting
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: A1=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)Drug: B2=Glimepiride / Vildagliptin / Metformin (1 mg/ 50 mg/ 500 mg)Drug: (A2) Glimepiride/Vildagliptin/MetforminDrug: (B2) Glimepiride/Vildagliptin/Metformin
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2023-11-01
- Lead Sponsor
- Laboratorios Silanes S.A. de C.V.
- Target Recruit Count
- 172
- Registration Number
- NCT04841096
- Locations
- 🇲🇽
Mérida Investigación Clínica, Merida, Yucatan, Mexico
🇲🇽Centro de Investigación Médica Aguascalientes, Aguascalientes, Mexico
🇲🇽Oaxaca Site Management Organization SC., Oaxaca, Mexico
Metformin Glycinate in Patients With MS or DM2 , Hospitalized With COVID-19 and SARS Secondary to SARS-CoV-2
Phase 2
Withdrawn
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2Metabolic SyndromeType 2 Diabetes
- Interventions
- Drug: Placebo oral tablet
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Laboratorios Silanes S.A. de C.V.
- Registration Number
- NCT04626089
- Locations
- 🇲🇽
Hospital Juárez de México, OPD, Mexico City, Mexico
Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.
Phase 2
Completed
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2
- Interventions
- Drug: Placebo oral tablet
- First Posted Date
- 2020-11-12
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Laboratorios Silanes S.A. de C.V.
- Target Recruit Count
- 20
- Registration Number
- NCT04625985
- Locations
- 🇲🇽
The American British Cowdray Medical Center, I.A.P, Mexico City, Mexico
Fixed Dose Combination of Fluoxetin and Metformin in the Management of Overweight and Obesity
Phase 2
Suspended
- Conditions
- Overweight and Obesity
- Interventions
- First Posted Date
- 2017-02-13
- Last Posted Date
- 2017-09-01
- Lead Sponsor
- Laboratorios Silanes S.A. de C.V.
- Target Recruit Count
- 150
- Registration Number
- NCT03051451
- Locations
- 🇲🇽
Laboratorios SIlanes S.A. de C.V,, Mexico Distrito Federal, Mexico City, Mexico
Efficacy Study of Metformin Glycinate on Postprandial Lipemia
- First Posted Date
- 2014-02-17
- Last Posted Date
- 2018-01-30
- Lead Sponsor
- Laboratorios Silanes S.A. de C.V.
- Target Recruit Count
- 72
- Registration Number
- NCT02064881
- Locations
- 🇲🇽
Instituto Nacional de Ciencias Médicas Y Nutrición Salvador Zubirán, México, Distrito Federal, Mexico
Metformin vs Conjugated Linoleic Acid and an Intervention Program With Healthy Habits in Obese Children
Phase 2
- Conditions
- Obesity
- Interventions
- Dietary Supplement: Conjugated Linoleic AcidDrug: PlaceboBehavioral: Healthy habits program
- First Posted Date
- 2014-02-14
- Last Posted Date
- 2014-02-14
- Lead Sponsor
- Laboratorios Silanes S.A. de C.V.
- Target Recruit Count
- 120
- Registration Number
- NCT02063802
- Locations
- 🇲🇽
General Hospital of Mexico, Mexico, Distrito Federal, Mexico
© Copyright 2025. All Rights Reserved by MedPath